Skip to main content
SpringerLink
Log in

Neuroprotection in Amyotrophic Lateral Sclerosis

  • Protocol
  • First Online:
The Handbook of Neuroprotection

Part of the book series: Springer Protocols Handbooks ((SPH))

Abstract

Amyotrophic lateral sclerosis (ALS) is progressive, devastating syndrome that affects both upper and motor neurons. It results in limbs and facial motor weakness, atrophy, spasticity, and death due to respiratory paralysis occurs in 3–5 years. It is referred to as motor neuron disease in UK and some other European countries and as Charcot’s disease in France. It is also referred to as Lou Gehrig’s disease in the US.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696–9.

    Article  CAS  Google Scholar 

  • Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:481–8.

    Article  CAS  Google Scholar 

  • ALSUntangled Group. ALSUntangled No. 7: Investigating hyperimmune goat serum (Aimspro) for ALS. Amyotroph Lateral Scler 2010;11:571–3.

    Article  Google Scholar 

  • Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol 2013;260:1901–6.

    Article  CAS  Google Scholar 

  • Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology 2018;90:e565–e574.

    Article  CAS  Google Scholar 

  • Bozik ME, Mather JL, Kramer WG, Gribkoff VK, Ingersoll EW. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol 2010;51:1177–85.

    Article  Google Scholar 

  • Brenner D, Yilmaz R, Müller K, et al. Hot-spot KIF5A mutations cause familial ALS. Brain 2018; 141:688–697.

    Article  Google Scholar 

  • Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med 2017;377:162–172.

    Article  CAS  Google Scholar 

  • Burberry A, Suzuki N, Wang JY, et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci Transl Med 2016;8:347ra93.

    Article  Google Scholar 

  • Cashman N, Tan LY, Krieger C, et al. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 2008;37:620–5.

    Article  CAS  Google Scholar 

  • Choi MR, Kim HY, Park JY, et al. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010;472:94–8.

    Article  CAS  Google Scholar 

  • Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009;10:99–106.

    Article  CAS  Google Scholar 

  • Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:1083–1091.

    Article  CAS  Google Scholar 

  • Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013;12:1059–67.

    Article  CAS  Google Scholar 

  • Daniel B, Green O, Viskind O, Gruzman A. Riluzole increases the rate of glucose transport in L6 myotubes and NSC-34 motor neuron-like cells via AMPK pathway activation. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:434–43.

    Article  CAS  Google Scholar 

  • Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014;75:363–73.

    Article  Google Scholar 

  • Ferraiuolo L, Meyer K, Sherwood TW, et al. Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A 2016;113:E6496–E6505.

    Article  CAS  Google Scholar 

  • Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. PNAS 2008;105:2052–57.

    Article  CAS  Google Scholar 

  • Fumagalli E, Funicello M, Rauen T, et al. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 2008;578:171–6.

    Article  CAS  Google Scholar 

  • Gaj T, Ojala DS, Ekman FK, et al. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv 2017;3(12):eaar3952.

    Article  Google Scholar 

  • Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2016:1–9.

    Google Scholar 

  • Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012;30:1144–51.

    Article  CAS  Google Scholar 

  • Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008;14:215–26.

    Article  CAS  Google Scholar 

  • Ivanov P, O’Day E, Emara MM, et al. G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments. Proc Natl Acad Sci U S A 2014;111:18201–6.

    Article  CAS  Google Scholar 

  • Izumi Y, Sawada H, Yamamoto N, et al. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 2007;557:132–40.

    Article  CAS  Google Scholar 

  • Jain KK. Glatiramer acetate. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019.

    Google Scholar 

  • Jain KK. Riluzole. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019a.

    Google Scholar 

  • Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009;66:235–44

    Article  CAS  Google Scholar 

  • Kindy M, Lupinacci P, Chau R, et al. A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C). F1000Research 2017; 6:230 (https://doi.org/10.12688/f1000research.10519.1)

    Article  Google Scholar 

  • Kramer NJ, Haney MS, Morgens DW, et al. CRISPR-Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity. Nat Genet 2018; 50:603–612.

    Article  CAS  Google Scholar 

  • Landers JE, Melki J, Meininger V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. PNAS 2009;106:9004–9.

    Article  CAS  Google Scholar 

  • Lauria G, Campanella A, Filippini G, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 2009;10:410–5.

    Article  CAS  Google Scholar 

  • Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol 2014;21:529–36.

    Article  CAS  Google Scholar 

  • Liu AY, Mathur R, Mei N, et al. Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival. J Biol Chem 2011;286:2785–94.

    Article  CAS  Google Scholar 

  • Maier A, Deigendesch N, Müller K, et al. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study. PLoS One 2015;10:e0139684.

    Article  Google Scholar 

  • Marchetto MC, Muotri AR, Mu Y, et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008;3:649–57.

    Article  CAS  Google Scholar 

  • McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest 2018;128:3558–3567.

    Article  Google Scholar 

  • Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009;10:378–83.

    Article  CAS  Google Scholar 

  • Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1{beta} accelerates ALS pathogenesis. PNAS 2010;107:13046–50.

    Article  CAS  Google Scholar 

  • Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;3:CD001447.

    Google Scholar 

  • Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435–42.

    Article  CAS  Google Scholar 

  • Mitropoulos K, Katsila T, Patrinos GP, Pampalakis G. Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis. OMICS 2018;22:52–64.

    Article  CAS  Google Scholar 

  • Nanou A, Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 2009;175:187–200.

    Article  CAS  Google Scholar 

  • Neymotin A, Petri S, Calingasan NY, et al. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220:191–7.

    Article  CAS  Google Scholar 

  • Niimori-Kita K, Tamamaki, N, Koizumi D, Niimori D. Matrin-3 is essential for fibroblast growth factor 2-dependent maintenance of neural stem cells. Sci Rep 2018;8:13412.

    Article  Google Scholar 

  • Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:266–71.

    Article  CAS  Google Scholar 

  • Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest 2015;125:1767–79.

    Article  Google Scholar 

  • Phatnani HP, Guarnieri P, Friedman BA, et al. Intricate interplay between astrocytes and motor neurons in ALS. Proc Natl Acad Sci U S A 2013;110:E756–65.

    Article  CAS  Google Scholar 

  • Riley J, Federici T, Polak M, et al. Intraspinal Stem Cell Transplantation in ALS: A Phase I Safety Trial, Technical Note & Lumbar Safety Outcomes. Neurosurgery 2012;71:405–16.

    Article  Google Scholar 

  • Rothstein JD. Current hypothesis for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009;65(suppl):S3–9.

    Article  CAS  Google Scholar 

  • Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother 2017;18:735–8.

    Article  CAS  Google Scholar 

  • Shi KY, Mori E, Nizami ZF, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A 2017;114:E1111–E1117.

    Article  CAS  Google Scholar 

  • Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71:1770–5.

    Article  CAS  Google Scholar 

  • Strong MJ. The evidence for altered RNA metabolism in amyotrophic lateral sclerosis (ALS). J Neurol Sci 2010;288:1–12.

    Article  CAS  Google Scholar 

  • Sun MM, Bu H, Li B, et al. Neuroprotective potential of phase II enzyme inducer diallyl trisulfide. Neurol Res 2009;31:23–7.

    Article  Google Scholar 

  • Therrien M, Dion PA, Rouleau GA. ALS: recent developments from genetics studies. Curr Neurol Neurosci Rep 2016;16: 59–71.

    Article  Google Scholar 

  • Vaccaro A, Patten SA, Aggad D, et al. Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. Neurobiol Dis 2013;55:64–75.

    Article  CAS  Google Scholar 

  • Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418–22.

    Article  Google Scholar 

  • van Zundert B, Brown RH Jr. Silencing strategies for therapy of SOD1-mediated ALS. Neurosci Lett 2017;636:32–39.

    Article  Google Scholar 

  • Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler 2008;9:50–8.

    Article  Google Scholar 

  • Wang H, O’Reilly EJ, Weisskopf MG, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 2011;173:595–602.

    Article  Google Scholar 

  • Williams AH, Valdez G, Moresi V, et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapse in mice. Science 2009;326;1549–54.

    Article  CAS  Google Scholar 

  • Wu R, Wang H, Xia XG, et al. Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. Antioxid Redox Signal 2009;11:1523–34.

    Article  CAS  Google Scholar 

  • Yonashiro R, Tahara EB, Bengtson MH, et al. The Rqc2/Tae2 subunit of the ribosome-associated quality control (RQC) complex marks ribosome-stalled nascent polypeptide chains for aggregation. Elife 2016;5. pii: e11794.

    Article  Google Scholar 

  • Zhang F, Strom AL, Fukada K, et al. Interaction between Familial Amyotrophic Lateral Sclerosis (ALS)-linked SOD1 Mutants and the Dynein Complex. J Biol Chem 2007;282:16691–9.

    Article  CAS  Google Scholar 

  • Zhang Y, Cook A, Kim J, et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2013;55:26–35.

    Article  Google Scholar 

  • Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009;119:3437–49.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu C, Beck MV, Griffith JD, et al. Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2018;115:4661–4665.

    Article  CAS  Google Scholar 

  • Zoccolella S, Bendotti C, Beghi E, Logroscino G. Homocysteine levels and amyotrophic lateral sclerosis: A possible link. Amyotroph Lateral Scler 2010;11:140–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jain PharmaBiotech, Basel, Switzerland

    Kewal K. Jain

Authors
  1. Kewal K. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Jain, K.K. (2019). Neuroprotection in Amyotrophic Lateral Sclerosis. In: The Handbook of Neuroprotection. Springer Protocols Handbooks. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9465-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9465-6_10

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9464-9

  • Online ISBN: 978-1-4939-9465-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation